QUOTE AND NEWS
Forbes  Mar 26  Comment 
In trading on Thursday, the Gold Miners ETF (GDX) is outperforming other ETFs, up about 0.5% on the day.  Components of that ETF showing particular strength include shares of Harmony Gold Mining (HMY), up about 3.7% and shares of IAMGOLD (IAG),...
Forbes  Mar 25  Comment 
In trading on Wednesday, the Oil Services ETF (OIH) is outperforming other ETFs, up about 2.1% on the day.  Components of that ETF showing particular strength include shares of Transocean (RIG), up about 3.5% and shares of Ensco (ESV), up about...
Clusterstock  Mar 23  Comment 
Biogen shares spiked by more than 9% on Friday after it announced preliminary results for an Alzheimer's disease treatment called BIIB037. Stifel analysts had set a price target of $451 per share, and Biogen shot past that on Friday to as high...
Clusterstock  Mar 20  Comment 
Analysts are loving the latest news out of Biogen. On Friday, the company announced results on a test drug called aducanumab for Alzheimer's disease. Here's the key result, from the release: "Treatment with aducanumab produced a dose- and...
Forbes  Mar 19  Comment 
In trading on Thursday, the SPDR S&P Biotech ETF (XBI) is outperforming other ETFs, up about 2.2% on the day.  Components of that ETF showing particular strength include shares of Amicus Therapeutics (FOLD), up about 36.7% and shares of Inovio...
Market Intelligence Center  Mar 18  Comment 
S&P Biotech SPDR (XBI) traded between $229.94 and $233.50 before closing at $233.13 Tuesday and presents some attractive trading opportunities today. MarketIntelligenceCenter.com's algorithms have picked a Jun. '15 $230.00 covered call for a net...
Market Intelligence Center  Mar 16  Comment 
After closing Friday at $228.43, S&P Biotech SPDR (XBI) presents an attractive opportunity to get a 5.47% return in just 95 days, which is an annualized return of 21.02% (for comparison purposes only). To enter this trade, sell one Jun. '15...
Market Intelligence Center  Mar 12  Comment 
After a blockbuster 2014, the health care space continues its strong performance this year thanks to strong earnings growth, a merger and acquisition frenzy, corporate deals, and encouraging industry trends. While pharma stocks are flying higher,...
Forbes  Mar 4  Comment 
In trading on Wednesday, the SPDR S&P Biotech ETF (XBI) is outperforming other ETFs, up about 1.9% on the day.  Components of that ETF showing particular strength include shares of Orexigen Therapeutics (OREX), up about 13.6% and shares of...




RELATED WIKI ARTICLES
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki